An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
A woman in her early 30s shared that she began using GLP-1 drugs for weight loss in December 2025. She first took tirzepatide (brand name Mounjaro) up to 7.5 mg and lost about 1–1.5 kg (2–3 lbs) a week. When her weight hit 106 kg she switched to semaglutide (brand name Wegovy or Ozempic for diabetes) because of cost, and is now on the 2.4 mg dose. She still feels less hungry and tries to eat mindfully and move more, but her weight has slowed and she’s stuck around 101 kg despite the appetite suppression. Semaglutide and tirzepatide are medicines that act like natural gut hormones that tell your brain you’re full and slow down how fast your stomach empties. In plain terms: they make you feel less hungry and can help you eat less without feeling constantly deprived. Tirzepatide hits two different hormone targets and tends to produce faster, often larger weight loss; semaglutide targets one and also works well for many people. Both are prescription drugs, usually given by injection, and they’re used by some people for long-term weight management. The person’s story matches a common pattern researchers have observed: strong early weight loss with these drugs, then a slowdown or plateau after a few months. Clinical trials show big average weight losses, especially with higher doses, but real-world experiences vary a lot. Early weeks often bring the fastest drops because appetite drops and people naturally reduce calories. Over time the body adjusts — appetite can creep back up a bit, metabolism adapts, and weight loss slows. This anecdote doesn’t prove why her loss slowed — it could be the switch between drugs, dose differences, changes in exercise or diet consistency, or normal biological adaptation. Why this matters is practical. If you or someone you know is using these drugs, it’s normal to hit plateaus even when hunger feels reduced. Plateaus don’t mean the treatment “failed”; they’re a signal to reassess habits and supports. That can mean checking the dose and drug being used, working with a clinician or dietitian to tweak diet or physical activity, and considering behavioral supports for consistency. Cost and access also drive real-world decisions — switching drugs for affordability can change results, so that’s an important factor for many people. There are caveats and risks. These medicines aren’t magic: they work best combined with sustained lifestyle changes and medical follow-up. Side effects commonly include nausea, stomach upset, and sometimes gallbladder issues or pancreatitis in rare cases. Not everyone can or should take them — people with certain medical histories need careful review. Also, stopping the drug can lead to weight regain unless other long-term strategies are in place. Finally, this is one person’s report, not a controlled study, so it’s useful as a real-world example but not proof of how everyone will respond. Bottom line: GLP-1 drugs can sharply reduce appetite and drive early weight loss, but plateaus are common, and long-term success usually needs medical guidance, consistent habits, and attention to side effects and costs.
Source: r/Semaglutide